4R8-20652-13278
2 vaccinations
3 coded responses
22 check-ins
3 free-text entries
1 call case
- Sex
- Male
- Age at first dose
- 66+
- ZIP prefix
- 333 / FL
- Registered
- 2021-01-12
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-11
Dose 1 — Pfizer-BioNTech
-
2021-01-12
Registered in v-safe
- 2021-01-12
- 2021-01-14
- 2021-01-15
- 2021-01-17
- 2021-01-18
- 2021-01-25
-
2021-02-01
Dose 2 — Pfizer-BioNTech
- 2021-02-01
- 2021-02-02
- 2021-02-03
- 2021-02-04
- 2021-02-05
- 2021-02-06
- 2021-02-07
- 2021-02-08
-
2021-02-15
Survey response — day 14, dose 2MedDRA: Facial paralysis — Feeling: GoodFree text: Bilateral transient paralysis of anterior part of upper lip since 2 days following vaccine. Symptoms occur following chewing and impacts trying to drink from a can or bottle. Symptoms disappear completely after several minutes of inactive chewing.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-02-22
- 2021-03-01
- 2021-03-08
- 2021-03-15
- 2021-05-03
-
2021-08-04
Survey response — 6 months, dose 2MedDRA: Fatigue, SARS-CoV-2 test positive, Upper-airway cough syndrome — Feeling: GoodFree text: I tested positive for COVID-19 on May 21, 2021. Mild post-nasal drip and one day of being quite tired.MedDRA releases: 2021-09,2024-11 · check-in free text available
-
2022-02-01
Survey response — 12 months, dose 2MedDRA: COVID-19, Muscular weakness, Myasthenia gravis, Pre-existing disease, Reaction to previous exposure to any vaccine — Feeling: Good · Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Transient Myasthenia Gravis post 1st vaccine, worse after 2nd vaccine, and again after COVID-19 infection. Muscle weakness peri-oral, tongue, corner of mouth and eye (right side). Reported to VAERS.MedDRA releases: 2024-11 · check-in free text available
-
2022-02-01
Report sent to call center — 12 months, dose 2Get care from a doctor or other healthcare professionalOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-02-04
-
2022-02-10
Call successfulReported to VAERS voluntarily prior to GDIT contact
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-11 | Pfizer-BioNTech | |
| 2 | 2021-02-01 | Pfizer-BioNTech |
Call center
1 call center case
1 successful
VAERS report filed, before or during a call: 1
Free text
Release 4 — day 14, dose 2
Symptoms: Bilateral transient paralysis of anterior part of upper lip since 2 days following vaccine. Symptoms occur following chewing and impacts trying to drink from a can or bottle. Symptoms disappear completely after several minutes of inactive chewing.
Release 9 — 6 months, dose 2
Symptoms: I tested positive for COVID-19 on May 21, 2021. Mild post-nasal drip and one day of being quite tired.
Release 11 — 12 months, dose 2
Symptoms: Transient Myasthenia Gravis post 1st vaccine, worse after 2nd vaccine, and again after COVID-19 infection. Muscle weakness peri-oral, tongue, corner of mouth and eye (right side). Reported to VAERS.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | COVID-19 | · | · | ✓ |
| SD | Facial paralysis | ✓ | ✓ | ✓ |
| SD | Fatigue | ✓ | · | ✓ |
| SD | Muscular weakness | · | · | ✓ |
| SD | Myasthenia gravis | · | · | ✓ |
| SD | Pre-existing disease | · | · | ✓ |
| SD | Reaction to previous exposure to any vaccine | · | · | ✓ |
| SD | SARS-CoV-2 test positive | ✓ | · | ✓ |
| SD | Upper-airway cough syndrome | ✓ | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release